Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atezolizumab + carboplatin + cyclophosphamide
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Atezolizumab + carboplatin + cyclophosphamide is a combination regimen consisting of three distinct drugs used in oncology. Atezolizumab is a monoclonal antibody that targets programmed death-ligand 1 (PD-L1), acting as an immune checkpoint inhibitor to enhance the anti-tumor immune response. Carboplatin and cyclophosphamide are both small molecule chemotherapeutic agents; carboplatin is a platinum-based compound that induces DNA crosslinking and apoptosis, while cyclophosphamide is an alkylating agent that interferes with DNA replication and cell division. This combination aims to leverage the immunomodulatory effects of atezolizumab with the cytotoxic actions of carboplatin and cyclophosphamide for synergistic anti-cancer activity.
- Brand names
- Tecentriq + Paraplatin + Cytoxan
- Other names
- carboplatin + cyclophosphamide + atezolizumabatezolizumab + carboplatin + cyclophosphamide combination
02
Targets
DNACD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on atezolizumab + carboplatin + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atezolizumab + carboplatin + cyclophosphamide.